Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017

The team blocked a signal in the cancer cell with a non-toxic drug. Credit: University of York

Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Now that this mechanism has been identified, however, scientists at York have found a way to block the signal in the cancer cells, disabling the cell and preventing it from multiplying at a new site in the body.

Their research showed that the protein, which normally functions to reduce inflammation after infections, has a key-like structure that locks on to opposite receptors on the stem cells of prostate cancer. This allows cancer cells that have spread from the prostate to 'dock' with the protein in the bones and multiply to form a new tumour.

Once the prostate cancer has attached to the protein, a signal is sent from the surface of the cancer to the nucleus of the cell, telling it that it can start to grow.

Like a 'space rocket'

Professor Norman Maitland, from the University's Department of Biology, said: "We have always known that the two places where prostate cancer spreads are the bones and lymph nodes, but we have not fully understood why these two locations are preferred.

"If we imagine the prostate cancer cell as a floating 'space rocket' and the only way for it to perform its mission is to 'dock' with another 'space vehicle', we start to get a picture of what happens when a cancer cell moves around the body in search of a new home.

"Without this docking station, the 'ship', or cell, will just float around, not causing any further harm. The receptors on the 'docking station', or the protein in bone, act like a magnet for the receptors on the stem cells of the cancer and once it is 'docked', getting rid of the cancer becomes much harder."

Blocking the signal

Replicating this 'docking process' in human prostate cancer cells, the team were able to identify the signal going into the nucleus of the cancer cell and blocked it with a non-toxic drug that has previously been tested for treatment of Allergic Asthma.

They found that the drug inhibits the signal, allowing the cancer cell to survive, but ultimately disabling its ability to spread. This could mean that cancer spread can be slowed down or be made more receptive to cell death following traditional treatments such as chemotherapy.

Drug discovery

Professor Maitland said: "We know that this works in human cancer cells, but what we now need to find is the correct dosage of the drug in patients, and whether it will buy a man more time to fight his cancer or even stop the spread of cancer altogether".

"Clinical trials are some way off, but this is a positive and exciting step forward in tackling this disease and reducing the number of deaths."

Related Stories

ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics, Inc., USA and ...

Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting ...

Researchers have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute ...

Recommended for you

As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.